VIR vs. RARE, AKRO, MOR, SWTX, PTGX, CPRX, MRUS, ALVO, APLS, and SRRK
Should you be buying Vir Biotechnology stock or one of its competitors? The main competitors of Vir Biotechnology include Ultragenyx Pharmaceutical (RARE), Akero Therapeutics (AKRO), MorphoSys (MOR), SpringWorks Therapeutics (SWTX), Protagonist Therapeutics (PTGX), Catalyst Pharmaceuticals (CPRX), Merus (MRUS), Alvotech (ALVO), Apellis Pharmaceuticals (APLS), and Scholar Rock (SRRK). These companies are all part of the "pharmaceutical products" industry.
Vir Biotechnology vs.
Vir Biotechnology (NASDAQ:VIR) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, media sentiment, risk, profitability and community ranking.
In the previous week, Ultragenyx Pharmaceutical had 3 more articles in the media than Vir Biotechnology. MarketBeat recorded 7 mentions for Ultragenyx Pharmaceutical and 4 mentions for Vir Biotechnology. Ultragenyx Pharmaceutical's average media sentiment score of 1.28 beat Vir Biotechnology's score of 0.59 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media.
Ultragenyx Pharmaceutical received 781 more outperform votes than Vir Biotechnology when rated by MarketBeat users. Likewise, 77.52% of users gave Ultragenyx Pharmaceutical an outperform vote while only 56.44% of users gave Vir Biotechnology an outperform vote.
65.3% of Vir Biotechnology shares are owned by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. 15.6% of Vir Biotechnology shares are owned by company insiders. Comparatively, 5.5% of Ultragenyx Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Ultragenyx Pharmaceutical has higher revenue and earnings than Vir Biotechnology. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.
Vir Biotechnology has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500.
Vir Biotechnology currently has a consensus price target of $33.57, indicating a potential upside of 510.39%. Ultragenyx Pharmaceutical has a consensus price target of $92.79, indicating a potential upside of 159.98%. Given Vir Biotechnology's higher probable upside, equities analysts clearly believe Vir Biotechnology is more favorable than Ultragenyx Pharmaceutical.
Ultragenyx Pharmaceutical has a net margin of -101.60% compared to Vir Biotechnology's net margin of -678.40%. Vir Biotechnology's return on equity of -36.71% beat Ultragenyx Pharmaceutical's return on equity.
Summary
Ultragenyx Pharmaceutical beats Vir Biotechnology on 10 of the 18 factors compared between the two stocks.
Get Vir Biotechnology News Delivered to You Automatically
Sign up to receive the latest news and ratings for VIR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vir Biotechnology Competitors List
Related Companies and Tools
This page (NASDAQ:VIR) was last updated on 4/18/2025 by MarketBeat.com Staff
